Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features

Journal of Internal Medicine - Tập 257 Số 1 - Trang 6-17 - 2005
John P. Bilezikian1,2, Maria Luisa Brandi3, Mishaela R. Rubin1, Shonni J. Silverberg1
1From the Departments of Medicine
2Pharmacology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
3Department of Medicine, University of Florence, Florence, Italy

Tóm tắt

Abstract.

Primary hyperparathyroidism (PHPT) is characterized most commonly now as an asymptomatic disorder with hypercalcaemia and elevated levels of parathyroid hormone (PTH). The elevation in PTH is detected by both the standard immunoradiometric assays (IRMA) and a more recent IRMA that detects only the 1–84 full‐length PTH molecule. The serum calcium concentration is usually <1 mg dL−1 above normal. Recently, another variant of PHPT (normocalcaemic PHPT) has been described in which the serum calcium is normal but the serum PTH is elevated, in the absence of any secondary cause for PTH elevation. Although usually sporadic, PHPT also occurs in inherited syndromes. Skeletal manifestations are appreciated by densitometry showing a typical pattern in which cancellous bone of the lumbar spine is reasonably well preserved whilst the cortical bone of the distal third of the radius is preferentially reduced. Although reduced in incidence, renal stones remain the most common overt complication of PHPT. Other organs are theoretical targets of PHPT such as the neurobehavioural axis and the cardiovascular system. Vitamin D looms as an important determinant of the activity of the PHPT state. The 2002 NIH Workshop on asymptomatic PHPT has led to revised guidelines to help doctors determine who is best advised to have parathyroid surgery and who can be safely followed without surgery. New information about the natural history of PHPT in those who did not undergo surgery has helped to define more precisely who is at‐risk for complications. At the NIH workshop, a number of items were highlighted for further investigation such as pharmacological approaches to controlling hypercalcaemia, elevated PTH levels and maintaining bone density.

Từ khóa


Tài liệu tham khảo

10.1016/B978-012098651-4/50022-5

10.1056/NEJM198001243020402

10.1007/BF01726908

10.1055/s-0029-1210507

10.1159/000167216

10.1016/S0140-6736(73)91876-X

Geelhoed GW, 1989, Pseudogout as a clue and complication in primary hyperparathyroidism, Surgery, 106, 1036

10.1210/jcem.86.12.8070

10.1038/ng0897-375

10.1097/00005792-200201000-00001

Marx SJ, 2002, Hyperparathyroidism in hereditary syndromes: special expressions and special managements, J Bone Miner Res, 17, N37

Lepage R, 1998, A non(1–84)‐circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples, Clin Chem, 44, 805, 10.1093/clinchem/44.4.805

John MR, 1999, A novel immunoradiometric assay detects full‐length human PTH but not amino‐terminally truncated fragments: implications for PTH measurement in renal failure, J Clin Endocrinol Metab, 84, 4287, 10.1210/jcem.84.11.6236

10.1359/jbmr.2001.16.4.605

10.1210/jc.2002-021266

10.1210/jc.2003-031014

10.1210/jcem-67-6-1294

10.1210/jc.80.3.723

10.1002/jbmr.5650040302

Bilezikian JP, 1991, Characterization and evaluation of asymptomatic primary hyperparathyroidism, J Bone Miner Res, 6, 585

10.1210/jc.81.11.4007

10.1210/jcem-70-4-930

Parfitt AM., 1989, Clinical Disorders of Bone and Mineral Metabolism, 7

10.1002/jbmr.5650100917

10.1002/jbmr.5650070808

10.1210/jc.84.5.1562

10.7326/0003-4819-83-3-365

10.1001/archinte.147.11.1951

10.7326/0003-4819-109-12-959

10.1111/j.1365-2796.1993.tb01017.x

10.1016/S0039-6060(05)80017-0

10.1359/jbmr.1999.14.10.1700

10.1016/S8756-3282(98)00042-8

10.1359/jbmr.2002.17.10.1741

Bilezikian JP., 2003, Bone strength in primary hyperparathyroidism, Osteoporos Int, 14, 5113

10.1097/00005792-197403000-00002

10.1056/NEJM198002213020801

10.1016/0002-9343(90)90346-F

10.1016/B978-012098651-4/50029-8

10.1210/jcem-53-3-536

Silverberg SJ., 2003, Non‐classical target organs in primary hyperparathyroidism, J Bone Miner Res, 17, N117

10.7326/0003-4819-79-4-566

10.7326/0003-4819-80-2-182

10.1016/S0002-9343(89)80613-8

Joborn C, 1998, Psychiatric morbidity in primary hyperparathyroidism, World J Surg, 2, 476

10.1016/0002-9343(94)90128-7

Clark OH., 1994, Presidential address: ‘Asymptomatic’ primary hyperparathyroidism: is parathyroidectomy indicated, Surgery, 116, 947

10.1007/s002689900428

10.1016/S0039-6060(99)70224-2

10.1067/msy.2000.110844

Brown GG, 1987, Neurobehavioral symptoms in mild hyperparathyroidism: related to hypercalcemia but not improved by parathyroidectomy, Henry Ford Med J, 35, 211

10.1016/0002-9343(78)90748-9

10.1001/archinte.141.13.1761

10.1136/hrt.54.5.539

Diamond TH, 1987, Hypercalcemia due to parathyroid adenoma and hypertrophic cardiomyopathy, S Afr Med J, 71, 448

10.1016/0002-9343(93)90260-V

Niederle B, 1990, Cardiac calcific deposits in patients with primary hyperparathyroidism: preliminary results of a prospective echocardiographic study, Surgery, 108, 1052

10.1210/jc.85.5.1815

10.1067/msy.2099.101422

10.1016/S0008-6363(98)00177-1

10.1210/jcem.85.10.6880

Rubin MR, 2002, Vascular stiffness is increased in patients with primary hyperparathyroidism, J Bone Miner Res, 17, S381

10.1046/j.1365-2796.1998.00281.x

10.1016/B978-012098651-4/50037-7

Norton JA, 1987, Effect of parathyroidectomy in patients with Zollinger‐Ellison syndrome and MEN1. A prospective study, Surgery, 102, 958

10.1210/jcem.86.12.8070

10.1001/jama.243.3.246

10.1111/j.1365-2265.1995.tb02043.x

Meng XW, 1994, The diagnosis of primary hyperparathyroidism – analysis of 134 cases, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 16, 13

10.4158/EP.2.4.250

10.1016/0002-9343(74)90812-2

Silverberg SJ, Vitamin D deficiency in primary hyperparathyroidism, Am J Med, 107, 561, 10.1016/S0002-9343(99)00294-6

Palmer M, 1987, Mortality after surgery for primary hyperparathyroidism. A follow‐up of 441 patients operated on from 1956 to 1979, Surgery, 102, 1

10.1016/S0140-6736(87)91906-4

10.1016/S0002-9343(97)00270-2

National Institutes of Health., 1991, Consensus development conference statement on primary hyperparathyroidism, J Bone Miner Res, 6, s9

Bilezikian JP, 2002, Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century, J Bone Miner Res, 17, N2

10.1001/archsurg.134.10.1119

10.1016/S0753-3322(00)80020-7

Colli E, 2004, Forearm autograft recurrence after 37 consecutive total parathyroidectomies for primary hyperparathyroidism in MEN1 syndrome, J Intern Med, 255, 715

Marx SJ., 2001, The Metabolic and Molecular Bases of Inherited Disease, 943

Norton KS, 2001, Use of the Sestamibi scan to identify hyperplastic parathyroid tissue in the forearm of a patient with MEN1 syndrome, J La State Med Soc, 153, 605

10.1067/msy.2001.118379

Deaconson TF, 1987, The effect of parathyroidectomy on the recurrence of nephrolithiasis, Surgery, 215, 241

10.1056/NEJMcp032200

10.1210/jc.83.3.732

Tritos NA, 1999, Rapid improvement of osteoporosis following parathyroidectomy in a premenopausal woman with acute primary hyperparathyroidism, Arch Intern Med, 139, 1498

DiGregorio S., 1999, Hiperparatiroidismo primario: dramatico incremento de la masa ostea post paratiroidectomia, Diagn Osteol, 1, 11

10.1056/NEJM199910213411701

Parfitt AM, 1991, Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: clinical course and considerations bearing on the need for surgical intervention, J Bone Miner Res, 6, S97

10.1210/jcem-67-1-62

10.1210/jc.76.1.103

10.1210/jcem-70-5-1334

10.1056/NEJM198510313131805

10.1016/S0002-9343(97)00053-3

10.1016/S0140-6736(72)90173-0

10.7326/0003-4819-100-5-633

10.1056/NEJM198606053142304

10.7326/0003-4819-125-5-199609010-00002

10.1001/jama.288.3.321

Marcus R., 2002, The role of estrogens and related compounds in the management of primary hyperparathyroidism, J Bone Miner Res, 17, N146

10.1210/jc.2002-020667

10.1002/j.1552-4604.1977.tb04624.x

10.7326/0003-4819-95-1-23

10.1097/00019616-200111000-00006

10.1359/jbmr.2001.16.1.113

10.1210/jc.2002-020890

10.1210/jc.2003-030908

10.1210/jc.77.4.1067

10.1056/NEJM199507273330407

10.1056/NEJM199711203372104

10.1210/jc.2002-021597

10.1016/0002-9343(54)90353-8